AVALIDE 12.5 MG
HYDROCHLOROTHIAZIDE : 12.5 MG IRBESARTAN : 300 MG · DIN 02241819 · SANOFI-AVENTIS CANADA INC
Health Canada status: MARKETED
What is AVALIDE?
AVALIDE 12.5 MG contains HYDROCHLOROTHIAZIDE : 12.5 MG IRBESARTAN : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 02241819, held by SANOFI-AVENTIS CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 14-May-2007. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AVALIDE used for?
AVALIDE ® (irbesartan/hydrochlorothiazide) is indicated: • for the treatment of essential hypertension in patients for whom combination therapy is appropriate (see DOSAGE AND ADMINISTRATION). • as initial therapy in patients with severe essential hypertension (Sitting DBP ≥ 110 mmHg) for whom the benefit of a prompt blood pressure reduction exceeds the risk of initiating combination therapy in these patients (see CLINICAL TRIALS and DOSAGE AND ADMINISTRATION).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is AVALIDE called?
The same molecule, IRBESARTAN AND DIURETICS, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Aprovel | Latin | Bahrain, Iceland, Morocco, Norway, Sweden |
| CoAprovel | Latin | Bahrain, Norway, Sweden |
| Irbesartan Sandoz | Latin | Australia, Norway, Sweden |
| Karvea | Latin | Australia, Sweden |
| Irbesartan/Hydroklortiazid Actavis | Latin | Norway, Sweden |
| APO-Irbesartan | Latin | Australia |
| APO-Irbesartan HCTZ | Latin | Australia |
| AVSARTAN | Latin | Australia |
| Blooms Irbesartan | Latin | Australia |
| Ifirmasta | Latin | Czechia, Sweden |
| Irbesartan Actavis | Latin | Norway, Sweden |
| IRBESARTAN-WGR | Latin | Australia |
| Irbesartan/HCT Sandoz | Latin | Australia |
| Ifirmacombi | Latin | Czechia, Sweden |
| Irbesartan Hydrochlorothiazide Zentiva | Latin | Sweden |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02241819 |
|---|---|
| Brand name | AVALIDE |
| Generic / active ingredient | HYDROCHLOROTHIAZIDE : 12.5 MG IRBESARTAN : 300 MG |
| Manufacturer | SANOFI-AVENTIS CANADA INC |
| Strength | 12.5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C09DA04 IRBESARTAN AND DIURETICS |
| AHFS class | 24:32.08 ; 40:28.20 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 14-May-2007 |
| Original market date | 2000-03-16 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02241819 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2241819 |
| Brand name | AVALIDE |
| Active ingredient / INN | HYDROCHLOROTHIAZIDE : 12.5 MG IRBESARTAN : 300 MG |
| ATC code | C09DA04 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C09 |
| AHFS class | 24:32.08 ; 40:28.20 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | SANOFI-AVENTIS CANADA INC |
How is it stored and handled?
null
How is it supplied?
bottles of 90 tablets
Which pack is which?
| Strength on the label | 12.5 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Packaging as described in the monograph | bottles of 90 tablets |
| Storage | null |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Is IRBESARTAN AND DIURETICS in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C09DA04 IRBESARTAN AND DIURETICS. 17 of 67 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AVALIDE | 150 MG | TABLET | SANOFI-AVENTIS CANADA INC | MARKETED | DIN 02241818 |
| IRBESARTAN HCT | 12.5 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02385325 |
| IRBESARTAN HCT | 150 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02385317 |
| IRBESARTAN HCT | 300 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02385333 |
| IRBESARTAN-HCTZ | 150 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02365162 |
| IRBESARTAN-HCTZ | 25 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02365189 |
| IRBESARTAN-HCTZ | 300 MG | TABLET | PRO DOC LIMITEE | MARKETED | DIN 02365170 |
| PMS-IRBESARTAN-HCTZ | 12.5 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02328526 |
| PMS-IRBESARTAN-HCTZ | 150 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02328518 |
| PMS-IRBESARTAN-HCTZ | 300 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02328534 |
Who else supplies IRBESARTAN AND DIURETICS worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. IRBESARTAN AND DIURETICS appears in 1256 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does IRBESARTAN AND DIURETICS cost around the world?
IRBESARTAN AND DIURETICS is listed on 21 national price registers Nexara tracks, across 626 pack listings published on 18 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Spain | PVP con IVA (public price) | 101 | 107 | 05 Sep 2026 |
| Australia | ex-manufacturer | 27 | 86 | 08 Sep 2026 |
| Saudi Arabia | public | 53 | 65 | 01 Sep 2026 |
| Sweden | AIP (pharmacy purchase price) | 15 | 60 | 03 Sep 2026 |
| United States | acquisition | 3 | 57 | 03 Sep 2026 |
| Italy | prezzo al pubblico (classe A) | 22 | 37 | 02 Sep 2026 |
| Greece | producer price (ex-factory) | 35 | 35 | 03 Sep 2026 |
| South Africa | single exit price | 27 | 32 | 01 Sep 2026 |
| Norway | max AUP (pharmacy retail) | 8 | 27 | 07 Sep 2026 |
| Romania | max producer price | 8 | 16 | 03 Sep 2026 |
| Luxembourg | reimbursement | 15 | 15 | 05 Sep 2026 |
| United Arab Emirates | public | 14 | 14 | 31 Aug 2026 |
| Belgium | public | 14 | 14 | 01 Sep 2026 |
| Bahrain | retail (max) | 6 | 14 | 01 Sep 2026 |
| Czechia | max producer price (ex-factory) | 4 | 11 | 03 Sep 2026 |
| Hungary | producer price (ex-factory) | 10 | 10 | 03 Sep 2026 |
| Slovakia | categorised final price | 6 | 9 | 02 Sep 2026 |
| Austria | KVP (Kassenverkaufspreis) | 6 | 6 | 03 Sep 2026 |
| United Kingdom | hospital | 6 | 6 | 31 Aug 2026 |
| Morocco | PPV (public price) | 1 | 4 | 05 Sep 2026 |
| Iceland | max wholesale | 1 | 1 | 02 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.